Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
Khaled Elshazly, Head of Oncology Clinical Pharmacists and the IV Admixture Unit at Agouza Hospital, shared a LinkedIn post about a recent article by Hanny Al-Samkari et al., published in The New England Journal of Medicine:
”Breakthrough in cancer care: Can we stop chemotherapy-induced thrombocytopenia (CIT) from delaying treatment?
A major challenge in oncology is having to reduce or delay life-saving chemotherapy because it destroys platelet-producing bone marrow cells. But a new global Phase 3 clinical trial just published in the New England Journal of Medicine (NEJM) offers a highly effective solution.
Led by investigators at Mass General Brigham, the trial evaluated Romiplostim vs. Placebo for Chemotherapy-Induced Thrombocytopenia (CIT).
Here are the game-changing results:
- The Trial: 165 patients (109 on romiplostim, 56 on placebo).
- The Impact: Patients taking romiplostim had a >10-fold lower odds of needing a chemotherapy dose reduction due to CIT.
- Efficacy: A remarkable 84% of patients in the romiplostim group required no chemotherapy dose modifications at all, compared to just 36% in the placebo group.
- Safety: The drug was well-tolerated. While overall adverse events were slightly higher in the treatment group, this primarily reflected the fact that these patients were successfully able to receive higher, un-reduced doses of their multi-agent chemotherapy.
Why this matters:
Romiplostim effectively boosts the bone marrow’s resilience, allowing patients to maintain their critical platelet counts. This means fewer treatment interruptions, optimal chemotherapy dosing, and better overall outcomes for cancer patients.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers